The European Medicines Agency (EMA) said on Tuesday it has extended its probe into Novo Nordisk’s diabetes drugs Ozempic and weight-loss treatment Saxenda, following two reports of suicidal thoughts, to include other drugs in the same class. The agency began its review on July 3 after Iceland’s health regulator flagged the reports of patients thinking … continue reading -> “EU Extends Ozempic Review to Include More Weight-loss, Diabetes Drugs “